表紙
市場調查報告書

硫酸脂酵素:開發中產品分析

Iduronate 2 Sulfatase - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 369088
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
硫酸脂酵素:開發中產品分析 Iduronate 2 Sulfatase - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 64 Pages
簡介

本報告提供以硫酸脂酵素為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關開發中之治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

硫酸脂酵素 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • AngioChem Inc.
  • ArmaGen Inc.
  • Bioasis Technologies Inc.
  • Green Cross Corporation
  • JCR Pharmaceuticals Co., Ltd.
  • Laboratorios Del Dr. Esteve S.A.
  • RegenxBio Inc.
  • Sangamo BioSciences, Inc.
  • Shire Plc

藥物簡介

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2278TDB

Summary

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome.

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed and Preclinical stages are 1, 2, 2, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and Cognitive Impairment.

The latest report Iduronate 2 Sulfatase - Pipeline Review, H1 2020, outlays comprehensive information on the Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
  • The report reviews Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

  • Global Markets Direct Report Coverage
  • Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Overview
  • Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Companies Involved in Therapeutics Development
  • Bioasis Technologies Inc
  • Denali Therapeutics Inc
  • Esteve Pharmaceuticals SA
  • GC Pharma
  • JCR Pharmaceuticals Co Ltd
  • RegenxBio Inc
  • Sangamo Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Drug Profiles
  • DNL-310 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EGT-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate Iduronate 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • idursulfase - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • idursulfase beta - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JR-141 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RGX-121 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SB-913 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • xB-3008 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Dormant Products
  • Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Discontinued Products
  • Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 29, 2020: REGENXBIO announces presentations at the 16th Annual WORLDSymposium 2020
  • Dec 18, 2019: REGENXBIO announces interim data from phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II)
  • Sep 09, 2019: CANbridge Pharmaceuticals' Hunterase Granted Priority Review by the Chinese National Medical Products Administration
  • Jul 29, 2019: CANbridge Pharmaceuticals submits New Drug Application for Hunterase for the treatment of Hunter Syndrome in China
  • Jun 11, 2019: Denali Therapeutics receives orphan drug and rare pediatric disease designation for DNL310, and expands its portfolio of brain penetrant enzyme replacement programs
  • Apr 02, 2019: Sangamo provided an update on its in vivo genome editing program: SB-913
  • Feb 28, 2019: JCR completes patient enrollment in phase 2 clinical trial of JR-141 for Hunter Syndrome in Brazil
  • Feb 28, 2019: JCR receives EMA Orphan Designation for JR-141 in Hunter Syndrome
  • Feb 07, 2019: Sangamo announces interim results of phase 1/2 CHAMPIONS study showing preliminary evidence of in vivo genome editing in patients with MPS II treated with SB-913
  • Feb 01, 2019: Sangamo Therapeutics to host conference call to review interim results from phase 1/2 CHAMPIONS study for Mucopolysaccharidosis type II
  • Jan 04, 2019: Sangamo announces upcoming clinical data Presentation on SB-913 At WORLDSymposium 2019
  • Dec 28, 2018: JCR completed enrollment in phase 3 clinical trial of JR-141 in Japan for Hunter syndrome
  • Dec 21, 2018: Notice on the publication of the phase 1/2 clinical trial results for hunter syndrome in molecular therapy
  • Oct 19, 2018: JCR Pharmaceuticals: Notice of Orphan Drug Designation by the US Food Drug Administration for JR-141 for Hunter Syndrome
  • Sep 05, 2018: Sangamo Announces 16 influential fall week clinical results including reductions in glycosaminoglycans in phase 1/2 trial evaluating SB-913, a zinc finger nuclease genome editing treatment for MPS II (Hunter Syndrome)
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Bioasis Technologies Inc, H1 2020
  • Pipeline by Denali Therapeutics Inc, H1 2020
  • Pipeline by Esteve Pharmaceuticals SA, H1 2020
  • Pipeline by GC Pharma, H1 2020
  • Pipeline by JCR Pharmaceuticals Co Ltd, H1 2020
  • Pipeline by RegenxBio Inc, H1 2020
  • Pipeline by Sangamo Therapeutics Inc, H1 2020
  • Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020